ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Encysive Pharmaceuticals has enlisted investment bank Morgan Stanley to help find a suitor after a series of setbacks for its lead product candidate. Last month, FDA issued a third "approvable" letter for Thelin, the Houston-based biotech firm's drug for high blood pressure in the pulmonary artery. The agency asked for more evidence of the drug's efficacy, further delaying its launch in the U.S. Encysive subsequently slashed its workforce by about 70% to 65 people to focus its remaining resources on getting Thelin to market in the U.S. This latest announcement from Encysive comes as Gilead Sciences prepares to launch its competing drug for pulmonary arterial hypertension, Letairis.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter